Adline Chem Lab Ltd
Incorporated in 1988, Adline Chem Lab Ltd trades in pharmaceutical formulations, Nutraceutical, and Dietary products.[1]
- Market Cap ₹ 8.01 Cr.
- Current Price ₹ 13.7
- High / Low ₹ 19.1 / 7.60
- Stock P/E
- Book Value ₹ -3.03
- Dividend Yield 0.00 %
- ROCE -933 %
- ROE %
- Face Value ₹ 10.0
Pros
Cons
- Company has low interest coverage ratio.
- Promoter holding is low: 25.8%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15.36 | 16.94 | 17.18 | 8.10 | 5.59 | 6.59 | 6.33 | 0.74 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 14.42 | 16.50 | 15.97 | 7.23 | 5.01 | 9.91 | 6.56 | 1.04 | 0.80 | 0.18 | 0.30 | 0.15 | |
| Operating Profit | 0.94 | 0.44 | 1.21 | 0.87 | 0.58 | -3.32 | -0.23 | -0.30 | -0.80 | -0.18 | -0.30 | -0.15 |
| OPM % | 6.12% | 2.60% | 7.04% | 10.74% | 10.38% | -50.38% | -3.63% | -40.54% | ||||
| 0.08 | 0.10 | 0.08 | 0.21 | 0.25 | 0.26 | 0.00 | 1.33 | -3.35 | 0.00 | 0.25 | 0.01 | |
| Interest | 0.48 | 0.44 | 0.32 | 0.34 | 0.07 | 0.02 | 0.03 | 0.01 | 0.00 | 0.12 | 0.16 | 0.18 |
| Depreciation | 0.51 | 0.09 | 0.96 | 0.73 | 0.73 | 0.42 | 1.02 | 0.35 | 0.09 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.03 | 0.01 | 0.01 | 0.01 | 0.03 | -3.50 | -1.28 | 0.67 | -4.24 | -0.30 | -0.21 | -0.32 |
| Tax % | 33.33% | 100.00% | 0.00% | 100.00% | 0.00% | 7.43% | 0.00% | -7.46% | 0.00% | -10.00% | -33.33% | -12.50% |
| 0.02 | 0.01 | 0.01 | 0.00 | 0.03 | -3.76 | -1.28 | 0.72 | -4.23 | -0.27 | -0.13 | -0.28 | |
| EPS in Rs | 0.03 | 0.02 | 0.02 | 0.00 | 0.05 | -6.43 | -2.19 | 1.23 | -7.23 | -0.46 | -0.22 | -0.48 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 12% |
| 3 Years: | % |
| TTM: | -115% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 28% |
| 1 Year: | -17% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 |
| Reserves | 1.21 | 1.21 | 1.19 | 1.18 | 1.18 | -2.64 | -3.92 | -3.20 | -7.42 | -7.22 | -7.34 | -7.62 |
| 9.25 | 9.01 | 9.94 | 11.32 | 5.35 | 2.85 | 2.50 | 1.32 | 1.33 | 1.36 | 1.49 | 1.80 | |
| 2.32 | 2.34 | 3.97 | 5.01 | 9.46 | 1.52 | 1.20 | 0.91 | 0.31 | 0.06 | 0.08 | 0.04 | |
| Total Liabilities | 18.63 | 18.41 | 20.95 | 23.36 | 21.84 | 7.58 | 5.63 | 4.88 | 0.07 | 0.05 | 0.08 | 0.07 |
| 10.08 | 10.27 | 12.68 | 12.45 | 11.99 | 4.78 | 3.64 | 4.43 | 0.00 | 0.00 | 0.00 | 0.00 | |
| CWIP | 0.20 | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 8.35 | 7.94 | 8.27 | 10.91 | 9.85 | 2.80 | 1.99 | 0.45 | 0.07 | 0.05 | 0.08 | 0.07 | |
| Total Assets | 18.63 | 18.41 | 20.95 | 23.36 | 21.84 | 7.58 | 5.63 | 4.88 | 0.07 | 0.05 | 0.08 | 0.07 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.39 | 0.83 | 2.46 | 0.89 | -0.95 | -11.34 | -0.29 | 0.21 | 0.01 | -0.17 | -0.23 | -0.16 | |
| -2.44 | -0.21 | -3.18 | -0.37 | -0.28 | 11.24 | 0.12 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 2.18 | -0.78 | 0.63 | 1.04 | -0.29 | -0.02 | -0.03 | -0.01 | 0.00 | 0.15 | 0.25 | 0.16 | |
| Net Cash Flow | 0.12 | -0.15 | -0.09 | 1.56 | -1.51 | -0.12 | -0.21 | 0.20 | 0.01 | -0.02 | 0.02 | 0.00 |
| Free Cash Flow | -2.06 | 0.62 | -0.73 | 0.36 | -1.23 | -0.10 | -0.17 | 0.21 | 0.01 | -0.17 | -0.23 | -0.16 |
| CFO/OP | 41% | 189% | 203% | 102% | -164% | 342% | 126% | -70% | -1% | 94% | 110% | 107% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 57.74 | 53.87 | 56.30 | 102.74 | 135.81 | 79.20 | 91.11 | 34.53 | ||||
| Inventory Days | 77.67 | 46.15 | 55.54 | 181.31 | 832.82 | 81.53 | 46.98 | 197.71 | 0.00 | |||
| Days Payable | 43.12 | 41.39 | 49.24 | 63.34 | 436.97 | 41.89 | 28.91 | 342.19 | ||||
| Cash Conversion Cycle | 92.30 | 58.62 | 62.60 | 220.71 | 531.66 | 118.84 | 109.18 | -109.95 | ||||
| Working Capital Days | 24.71 | -6.46 | -29.53 | -139.69 | -317.99 | -72.00 | -66.89 | -764.53 | ||||
| ROCE % | 3.39% | 2.84% | 2.00% | 1.98% | 0.59% | -40.35% | -23.83% | -10.95% | 5.90% | -933.33% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Permanent Employees Nos. |
|
|||||||||
| Total Number of Shareholders Nos. |
||||||||||
| Export Turnover INR Lakhs |
||||||||||
| Installed Capacity - Capsules Nos. in Lacs |
||||||||||
| Installed Capacity - Injectables Ltrs. in Lacs |
||||||||||
| Installed Capacity - Liquids Ltrs. in Lacs |
||||||||||
| Installed Capacity - Ointments Nos. in Lacs |
||||||||||
| Installed Capacity - Tablets Nos. in Lacs |
||||||||||
| Actual Production - Capsules Nos. in Lacs |
||||||||||
| Actual Production - Injectables Ltrs. in Lacs |
||||||||||
| Actual Production - Liquids Ltrs. in Lacs |
||||||||||
| Actual Production - Ointments Nos. in Lacs |
||||||||||
| Actual Production - Tablets Nos. in Lacs |
||||||||||
Extracted by Screener AI
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Newspaper Publication 30 May
-
Financial Results For 31.03.2026
29 May - Board approved audited standalone results for quarter and year ended March 31, 2026.
-
Board Meeting Outcome for Audited Standalone Financial Results Of The Company For The Quarter And Financial Year Ended 31.03.2026.
29 May - Board approved audited standalone results for FY2026 on 29 May 2026; net loss ₹28.11 lakh.
-
Board Meeting Intimation for Audited Standalone Financial Results Of The Company For The Quarter And Financial Year Ended March 31, 2026.
22 May - Board meeting on 29 May 2026 to approve audited standalone results for FY ended 31 March 2026.
-
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
30 Apr - Company confirms it is not a Large Corporate; annual disclosure not required for FY2026.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
ACLL is in the business of manufacturing pharmaceutical chemicals, fine chemicals,
and agrochemical products.